Altamira Therapeutics (FRA:2QA) Short Interest


FRA:2QA Altamira Therapeutics Ltd FRA:2QA
30 GF Score
Price €948.00
! 4 Warning Signs
View Full Analysis

What is Altamira Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:2QA vs IOBTQ, SCPX, CARM: Short Interest Comparison

For the Biotechnology subindustry, Altamira Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Altamira Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's Short Interest falls into.


FRA:2QA
30GF Score
Altamira Therapeutics Ltd FRA:2QA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altamira Therapeutics Business Description

Other Exchanges CYTOF:USA
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
30GF Score

Get the complete analysis for FRA:2QA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€948.00
Price